Daewon Pharmaceutical Co., Ltd.

Quick facts

Marketed products

• Kremezin granule
• Renamezin capsule · Infectious Disease
  Renamezin is an antibiotic that inhibits bacterial protein synthesis by binding to the bacterial ribosome.
• Telmisartan + Amlodipine · Cardiovascular
  Telmisartan blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload.

Phase 3 pipeline

• DW-0929
  DW-0929 is an investigational therapeutic agent in phase 3 development by Daewon Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.
• DW-330SR2 · Cardiovascular
  DW-330SR2 is a small molecule that targets the renin-angiotensin system.
• DW1026C1 · Diabetes
  DW1026C1 is a small molecule that targets the SGLT2 receptor.
• DW1026C2 · Diabetes
  DW1026C2 is a small molecule that targets the SGLT2 receptor.
• DW1026S · Diabetes
  DW1026S is a small molecule that targets the SGLT2 receptor.
• DW1601 · Diabetes
  DW1601 is a small molecule that targets the SGLT2 receptor.
• DW16011 · Diabetes
  DW16011 is a small molecule drug that targets the SGLT2 receptor.
• DW16012 · Diabetes
  DW16012 is a small molecule that targets the SGLT2 receptor.
• DW1903 · Diabetes
  DW1903 is a small molecule that targets the SGLT2 receptor.
• DW1903-R1 · Diabetes
  DW1903-R1 is a small molecule that targets the SGLT2 receptor.
• DW5121 · Diabetes
  DW5121 is a small molecule that targets the SGLT2 receptor.
• DW51211
  DW51211 is a small molecule drug that targets the molecular target.
• DW51212 · Diabetes
  DW51212 is a small molecule drug that targets the SGLT2 receptor.
• DW5421A · Diabetes
  DW5421A is a small molecule that targets the SGLT2 receptor.
• DWKH · Diabetes
  DWKH is a small molecule that targets the SGLT2 receptor.
• DWKH-R · Diabetes
  DWKH-R is a small molecule that targets the SGLT2 receptor.
• GLA5PR GLARS-NF1 · Oncology
  GLA5PR GLARS-NF1 is a glutaminyl-tRNA synthetase (GlnRS) inhibitor designed to selectively target and inhibit neurofibromatosis type 1 (NF1) mutant cells.
• Placebo drug of DW-1030
  Placebo drugs do not have an active pharmacological mechanism; they are used as controls in clinical trials.
• Placebo drug of Myonal Tab. · Musculoskeletal/Neurology (as comparator for Myonal)
  As a placebo, this drug contains no active pharmaceutical ingredient and produces no mechanistic effect beyond the placebo response.
• Reference(Stillen tab.) · Endocrinology
  Stillen is a medication used to treat hypothyroidism.
• Telmisartan + Amlodipine + Rosuvastatin · Cardiovascular
  Telmisartan is an angiotensin II receptor antagonist, amlodipine is a calcium channel blocker, and rosuvastatin is a statin.
• Telmisartan + Rosuvastatin · Cardiovascular
  Telmisartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure. Rosuvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis, thereby lowering LDL cholesterol.
• Test(DW1401) · unknown
  Test(DW1401) is a small molecule drug that targets the molecular target.
• Tramadol hydrochloride/Acetaminophen Tab. · Pain Management
  Tramadol inhibits norepinephrine and serotonin reuptake while acting as a weak opioid agonist, and acetaminophen reduces pain through central analgesic and antipyretic effects.

Phase 2 pipeline

• DW-3102

Phase 1 pipeline

• combination drug: DW330SR, DW1030
• DW-0919
• DW-0920
• DW1809
• DW1809-1
• DW1809-T2
• DW1903-R2
• DW340
• DW4421
• DW4421-1
• DW4421-2
• DW4421-N1
• DW4421-N2
• DW4421-N3
• DW4421-T1
• DW4421S
• DW4421S-T1
• DW5124
• DW5124-R
• DW5221
• DW5221-R
• DW5524
• DW5524-A

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Daewon Pharmaceutical Co., Ltd. portfolio CI brief
• Daewon Pharmaceutical Co., Ltd. pipeline updates RSS